If mutations that compromise function of the KLF6 transcription factor are indeed common in prostate cancer, we might then ask whether clustering analysis of data from molecular profiling of tumours (Ernst et al, 2002) would define KLF6 mutant tumours as a subgroup. This evidence concerns the gene KLF6 and prostate cancer.